

Press release from Emotra AB (publ)
Göteborg, October 27, 2021

Emotra AB (publ) announces that the publication of their interim report for the period Jan–Sep 2021 has been postponed to November 29

Today, October 27, 2021, the board of Emotra AB (publ) decided to postpone the publication of the company's interim report for the period Jan–Sep 2021 from October 28, 2021 to November 29, 2021.

The board of Emotra AB (in the process of changing its name to NeuraMetrix AB, which has not yet been registered) has decided to postpone the publication of the company's interim report from October 28, 2021 to November 29, 2021. The company is in the middle of a relisting process which, among other things, encompasses addressing a large amount of questions in an ongoing Due Diligence process. The company needs more time to reach to complete this objective.

The board has come to the conclusion that we need to have progressed further in this process before we can make a decision on the non-cash share issue that a resolution at the extraordinary shareholder meeting held on October 8, 2021 authorised the board to decide on. Therefore, we would be misleading the market if we published a semi-annual report that to a large extent describes what a future NeuraMetrix AB and its intended operations will look like.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR[®], is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB, AstraZeneca BioVentureHub, Pepparedsleden 1
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, www.emotra.se